INT161310

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 17
Total Number 20
Disease Relevance 8.75
Pain Relevance 2.74

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (LCK) aging (LCK) Golgi apparatus (LCK)
plasma membrane (LCK) cytoplasm (LCK)
Anatomy Link Frequency
lymphocyte 3
leukocyte 2
bowel 1
LCK (Homo sapiens)
Pain Link Frequency Relevance Heat
psoriasis 42 96.48 Very High Very High Very High
Inflammation 388 95.48 Very High Very High Very High
rheumatoid arthritis 71 95.20 Very High Very High Very High
Bioavailability 56 94.28 High High
cytokine 180 94.04 High High
mu opioid receptor 1 93.36 High High
Arthritis 140 91.16 High High
Opioid 6 89.44 High High
Morphine 3 85.12 High High
chemokine 16 80.36 Quite High
Disease Link Frequency Relevance Heat
Myeloid Leukemia 14 99.06 Very High Very High Very High
Chronic Myeloid Leukemia 14 98.96 Very High Very High Very High
Influenza Virus Infection 8 98.64 Very High Very High Very High
Graft Vs Host Disease 14 97.56 Very High Very High Very High
Psoriasis 42 96.48 Very High Very High Very High
Pressure And Volume Under Development 70 96.32 Very High Very High Very High
Inflammatory Bowel Disease 14 96.04 Very High Very High Very High
Disease 109 95.76 Very High Very High Very High
Rheumatoid Arthritis 71 95.20 Very High Very High Very High
Communicable Diseases 76 95.16 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This in turn activated protein kinase A, which augmented the kinase activity of C-terminal Src kinase bound to phosphoprotein associated with glycosphingolipid-enrich microdomains, resulting in a further enhancement of the tonic inhibition of the leukocyte-specific protein tyrosine kinase Lck, thereby blocking the initiation of TCR signaling.
Negative_regulation (inhibition) of Lck in leukocyte
1) Confidence 0.42 Published 2009 Journal J. Immunol. Section Abstract Doc Link 19561113 Disease Relevance 0.18 Pain Relevance 0.79
Csk phosphorylates leucocyte-specific tyrosine kinase (Lck), leading to the inhibition of Lck kinase activity.
Negative_regulation (inhibition) of Lck in leucocyte
2) Confidence 0.23 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2632733 Disease Relevance 0.56 Pain Relevance 0.03
A large number of compounds are reported to be potent inhibitors of Lck (see reference 5 in reference [44] in this review).
Negative_regulation (inhibitors) of Lck
3) Confidence 0.21 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.73 Pain Relevance 0.31
Lck inhibitors
Negative_regulation (inhibitors) of Lck
4) Confidence 0.21 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.76 Pain Relevance 0.37
Therefore, inhibition of Lck is likely to elicit an immunosuppressive effect that could be useful in the treatment of T-cell-mediated diseases like rheumatoid arthritis, inflammatory bowel disease, psoriasis, and organ graft rejection [32].
Negative_regulation (inhibition) of Lck in bowel associated with psoriasis, inflammation, rheumatoid arthritis, disease and graft vs host disease
5) Confidence 0.21 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.88 Pain Relevance 0.42
Compound 16, which is closely related to 15, is a modestly selective inhibitor of Lck with IC50?
Negative_regulation (inhibitor) of Lck
6) Confidence 0.21 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0 Pain Relevance 0.04
Compound 20 inhibited Lck with IC50?
Negative_regulation (inhibited) of Lck
7) Confidence 0.16 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.25 Pain Relevance 0.03
The anilinopyrimidine urea, 22, inhibited Lck with IC50?
Negative_regulation (inhibited) of Lck
8) Confidence 0.16 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.52 Pain Relevance 0.04
This review describes some of the recent developments in the search for inhibitors of IKK2, Syk, Lck, and JAK3 kinases.
Negative_regulation (inhibitors) of Lck
9) Confidence 0.16 Published 2008 Journal Purinergic Signal Section Abstract Doc Link PMC2721774 Disease Relevance 0.34 Pain Relevance 0.08
An anilinopyrimidine, 14, has been reported to inhibit Lck with IC50?
Negative_regulation (inhibit) of Lck
10) Confidence 0.16 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.43 Pain Relevance 0.17
This review will focus on the Lck inhibitors reported primarily in the years 2006–2007 and these publications refer to the earlier reports on Lck inhibitors.
Negative_regulation (inhibitors) of Lck
11) Confidence 0.16 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.56 Pain Relevance 0.20
A structurally related compound, A-770041, is an inhibitor of Lck (IC50?
Negative_regulation (inhibitor) of Lck
12) Confidence 0.15 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.13 Pain Relevance 0.05
Compound 23, a close structural analog of dasatinib (BMS-354825), a marketed kinase inhibitor drug for the treatment of chronic myelogenous leukemia (CML), is a potent, selective, and ATP-competitive inhibitor of Lck and other Src family kinases (IC50?
Negative_regulation (inhibitor) of Lck associated with myeloid leukemia and chronic myeloid leukemia
13) Confidence 0.15 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.64 Pain Relevance 0.08
Compound 17 is reported to be a modestly potent inhibitor of Lck (IC50?
Negative_regulation (inhibitor) of Lck
14) Confidence 0.15 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0 Pain Relevance 0.04
The pyrimidopyrazine derivative, 21, is reported to be a potent Lck inhibitor with IC50?
Negative_regulation (inhibitor) of Lck
15) Confidence 0.13 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.48 Pain Relevance 0.04
A series of benzimidazole-substituted anilinopyrimidines have been reported to be potent inhibitors of Lck.
Negative_regulation (inhibitors) of Lck
16) Confidence 0.13 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2721774 Disease Relevance 0.26 Pain Relevance 0.03
The decrease of the mRNA level of CD28, CD69 or LCK might be also linked in part to the decrease of the number of lymphocytes.
Negative_regulation (decrease) of LCK in lymphocytes
17) Confidence 0.04 Published 2010 Journal Immun Ageing Section Body Doc Link PMC2933667 Disease Relevance 0.33 Pain Relevance 0
However, the decrease of lymphocyte number was less marked than the large decrease of transcript levels of CD28, CD69 and LCK.
Negative_regulation (decrease) of LCK in lymphocyte
18) Confidence 0.04 Published 2010 Journal Immun Ageing Section Body Doc Link PMC2933667 Disease Relevance 0.75 Pain Relevance 0
However, the decrease of lymphocyte number was less marked than the large decrease of transcript levels of CD28, CD69 and LCK.
Negative_regulation (decrease) of LCK in lymphocyte
19) Confidence 0.03 Published 2010 Journal Immun Ageing Section Body Doc Link PMC2933667 Disease Relevance 0.74 Pain Relevance 0
TCR engagement recruits LCK and FYN, which are protein kinases initiating the TCR signaling pathway [45].
Negative_regulation (recruits) of LCK
20) Confidence 0.03 Published 2010 Journal Immun Ageing Section Body Doc Link PMC2933667 Disease Relevance 0.21 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox